0001564590-21-041202.txt : 20210805 0001564590-21-041202.hdr.sgml : 20210805 20210805080817 ACCESSION NUMBER: 0001564590-21-041202 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 211146426 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 8-K 1 atrs-8k_20210805.htm 8-K atrs-8k_20210805.htm
false 0001016169 0001016169 2021-08-05 2021-08-05

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2021

 

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

 

 

Delaware

 

1-32302

 

41-1350192

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

 

 

100 Princeton South, Suite 300, Ewing, NJ

 

08628

(Address of Principal Executive Offices)

 

(Zip Code)

(609) 359-3020

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

ATRS

 

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).  

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On August 5, 2021, Antares Pharma, Inc. (the “Company”) issued a press release announcing its operating and financial results for the second quarter ended June 30, 2021. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

 

 

99.1

  

Press Release issued by Antares Pharma, Inc., dated August 5, 2021

 

104

 

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

ANTARES PHARMA, INC.

 

 

 

 

 

Date:

 

August 5, 2021

 

By:

 

/s/ Fred M. Powell

 

 

 

 

Name:

 

Fred M. Powell

 

 

 

 

Title:

 

Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 atrs-ex991_19.htm EX-99.1 atrs-ex991_19.htm

EX99.1

      

 

  

 

 

 

 

ANTARES PHARMA REPORTS SECOND QUARTER 2021 FINANCIAL AND OPERATING RESULTS

 

Increased Revenue 39% Year-Over-Year to $45.0 Million

 

Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share

 

EWING, NJ, August 5, 2021 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today reported financial and operating results for the second quarter ended June 30, 2021 with record revenue of $45.0 million and net income of $4.4 million, or $0.03 per basic and diluted earnings per share.

 

Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “We believe our strong second quarter performance highlights the growth opportunities that prevail across our diversified business. XYOSTED and Teva’s generic EpiPen continue to be the primary drivers of our 39% year-over-year revenue increase and we continue to expect our full year revenue guidance to be in the range of $175-200 million. As we look ahead, we expect the advancement of our proprietary pipeline as well as our partner’s programs to support our future growth. With the unveiling of ATRS-1902 as hydrocortisone with a new autoinjector platform for adrenal crisis rescue, we are eager to initiate the PK study following the FDA’s recent acceptance of our IND submission. With our Quickshot autoinjector, we are also excited for our partner Idorsia’s initiation of their global Phase 3 study for selatogrel as a heart attack rescue pen as well as the potential NDA filing of Pfizer’s undisclosed rescue pen in the second half of 2021. Overall, we believe the diversification of our business remains foundational to our ongoing success.”

 

Second Quarter 2021 and Recent Highlights

 

 

•

XYOSTED® total prescriptions in the second quarter 2021 increased 50% year-over-year and 15% sequentially from first quarter 2021, according to IQVIA.

 

 

•

Teva’s generic EpiPen prescriptions increased 153% year-over-year, contributing to a 47% increase in EpiPen product and royalty revenue

 

 

•

Submitted the IND and received FDA acceptance for ATRS-1902 for adrenal crisis rescue

 

 

•

Partner Idorsia Ltd initiating global Phase 3 study with selatogrel for acute myocardial infarction

 

 

•

Completed $15.0 million principal pre-payment of Hercules term loan and reduced associated interest expense by $1.2 million annually

 

Second Quarter 2021 Financial Results

 

Total revenue generated from product sales, license and development activities and royalties was $45.0 million for the three months ended June 30, 2021, a 39% increase compared to $32.4 million in the same period in 2020.  For the six months ended June 30, 2021, total revenue was $87.1 million, a 33% increase from $65.5 million for the comparable period in 2020.

 

 

 

Product sales were $27.9 million for the three months ended June 30, 2021, a 13% increase compared to $24.7 million for the same period in 2020.  For the six months ended June 30, 2021, product sales were $57.0 million, a 10% increase from $51.8 million in the comparable period in 2020.   

Sales of our proprietary products XYOSTED®, OTREXUP® and NOCDURNA® generated revenue of $19.0 million and $37.7 million for the three and six months ended June 30, 2021, respectively, as compared to $14.8 million and $27.4 million for the three and six months ended June 30, 2020, respectively. The 28% and 37% increase in proprietary product sales for the three and six months ended June 30, 2021, respectively, compared to the same periods in 2020 were principally attributable to continued growth in prescriptions and sales of XYOSTED®.  

Partnered product sales were $9.0 million and $19.4 million for the three and six months ended June 30, 2021, respectively, as compared to $9.8 million and $24.4 million for the three and six months ended June 30, 2020, respectively. The net decrease in sales of partnered products for the second quarter and six months ended June 30, 2021 as compared to the same periods in 2020 is primarily attributable to a decrease in sales of sumatriptan to Teva and Makena® autoinjectors to AMAG.

 

Licensing and development revenue was $7.2 million and $12.2 million for the three and six month ended June 30, 2021, respectively, as compared to $2.7 million and $4.4 million for the comparable periods in 2020, respectively. The increase in licensing and development revenue for the three and six months ended June 30, 2021 was primarily a result of incremental development and maintenance activities with Teva and our other ongoing partnered development projects.

 

Royalty revenue was $9.9 million for the three months ended June 30, 2021 compared to $5.0 million for the same period in 2020.  For the six months ended June 30, 2021, royalty revenue was $17.9 million, as compared to $9.3 million for the same period in 2020.  The net increase in royalty revenue in the three and six months ended June 30, 2021 was attributable to an increase in royalties from Teva on their net sales of generic EpiPen®.

 

Research and development expenses were $4.0 million and $6.7 million for the three and six months ended June 30, 2021, respectively, as compared to $2.4 million and $5.4 million for the comparable periods in 2020, respectively. The increase in research and development costs incurred in 2021 as compared to 2020 was attributable to our ongoing internal development programs.

 

Selling, general and administrative expenses were $17.7 million and $35.3 million for the three and six months ended June 30, 2021, respectively, as compared to $14.4 million and $30.9 million for the comparable periods in 2020, respectively. The net increase in selling, general and administrative expenses for the three and six months ended June 30, 2021 was primarily due to an increase in sales and marketing expenses that had declined during the pandemic and incremental costs associated with NOCDURNA®. General and administrative expenses increased due to increases in compensation and professional services.

 

Net income was $4.4 million, or $0.03 per basic and diluted earnings per share for the second quarter 2021, compared to $2.2 million, or $0.01 per basic and diluted earnings per share in the same period in 2020.  Net income was $8.2 million, or $0.05 per basic and diluted earnings per share for the six months ended June 30, 2021 compared to a net loss of $0.2 million, or $0.00 loss per basic and diluted earnings per share in the comparable period of 2020.  

 

As of June 30, 2021, cash and cash equivalents were $45.1 million compared to $53.1 million as of December 31, 2020. In June 2021, Antares made a $15.0 million principal prepayment and reduced our loan balance with Hercules Capital to $25.0 million. The Company generated cash from operations of $8.4 million for the six months ended June 30, 2021.

 

Full-Year 2021 Financial Guidance

 

The Company today reaffirmed full-year 2021 revenue guidance in the range of $175-200 million, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to

2 of 7

 

 

 

supply or operations due to the ongoing COVID-19 pandemic.

 

Webcast and Conference Call Information

 

The Antares management team will provide a Company update and review the second quarter and year-to-date financial results via conference call and webcast today, August 5, 2021, at 8:30am ET (Eastern Time).  The webcast of the conference call will include a slide presentation, which can be accessed in the investor relations section of the Company’s website (www.antarespharma.com) under “Webcasts & Presentations”.  Alternatively, callers may participate in the audio portion of the conference call by dialing (800) 367-2403 for domestic callers and (334) 777-6978 for international callers.  Callers should reference the Antares Pharma conference call or conference ID number 3020992.

 

About Antares Pharma

 

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

 

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the Company’s ability to achieve the 2021 full-year revenue guidance; the uncertainty regarding the ongoing COVID-19 pandemic, including new strains of the virus, and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, clinical trials, and our overall business, operating results and financial condition; commercial success of XYOSTED® and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; future prescriptions and sales of OTREXUP®; successful commercialization of NOCDURNA® in the U.S. and market acceptance and future revenue from the same; whether the FDA will withdraw marketing approval for AMAG Pharmaceuticals’ Makena® subcutaneous auto injector following the FDA letter seeking withdrawal, whether AMAG will be granted an appeal hearing and if granted, whether  Makena® will be successful and future prescriptions, market acceptance and revenue from the same; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; Teva’s ability to successfully commercialize generic teriparatide in Europe, Canada and Israel and future revenue from the same, successful development including the timing and results of the Phase 3 trial of the drug device combination product for selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; the timing and results of the clinical development program for ATRS-1902 adrenal crisis rescue auto-injector, future NDA submission and FDA approval of the same, and if approved, future market acceptance and revenue for the same; FDA approval of Teva’s  ANDAs for both generic Forteo® and Byetta® and future revenue from the same; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development including the

3 of 7

 

 

 

Company’s urology assets in development as well as Pfizer’s undisclosed development product;  actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability  to repay the debt obligation to Hercules Capital;  the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

 

 

Contact:

Tram Bui

Vice President, Corporate Communications and Investor Relations

609-359-3016

tbui@antarespharma.com

 

 

 

TABLES FOLLOW


4 of 7

 

 

 

 

 

ANTARES PHARMA, INC.

Table 1 - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

 

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

Increase

 

 

June 30,

 

 

Increase

 

 

 

2021

 

 

2020

 

 

(Decrease)

 

 

2021

 

 

2020

 

 

(Decrease)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

27,904

 

 

$

24,665

 

 

13%

 

 

$

57,039

 

 

$

51,762

 

 

10%

 

Development and licensing revenue

 

 

7,167

 

 

 

2,687

 

 

167%

 

 

 

12,151

 

 

 

4,442

 

 

174%

 

Royalties

 

 

9,907

 

 

 

5,032

 

 

97%

 

 

 

17,871

 

 

 

9,259

 

 

93%

 

Total revenue

 

 

44,978

 

 

 

32,384

 

 

39%

 

 

 

87,061

 

 

 

65,463

 

 

33%

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

11,630

 

 

 

10,927

 

 

6%

 

 

 

24,128

 

 

 

24,941

 

 

(3)%

 

Cost of development revenue

 

 

4,810

 

 

 

1,550

 

 

210%

 

 

 

8,757

 

 

 

2,583

 

 

239%

 

Research and development

 

 

4,047

 

 

 

2,417

 

 

67%

 

 

 

6,687

 

 

 

5,398

 

 

24%

 

Selling, general and administrative

 

 

17,704

 

 

 

14,448

 

 

23%

 

 

 

35,311

 

 

 

30,870

 

 

14%

 

Total operating expenses

 

 

38,191

 

 

 

29,342

 

 

30%

 

 

 

74,883

 

 

 

63,792

 

 

17%

 

Operating income

 

 

6,787

 

 

 

3,042

 

 

123%

 

 

 

12,178

 

 

 

1,671

 

 

629%

 

Other expense

 

 

(1,224

)

 

 

(867

)

 

41%

 

 

 

(2,232

)

 

 

(1,852

)

 

21%

 

Net income (loss) before income taxes

 

 

5,563

 

 

 

2,175

 

 

156%

 

 

 

9,946

 

 

 

(181

)

 

**

 

Income tax expense

 

 

(1,143

)

 

 

—

 

 

**

 

 

 

(1,733

)

 

 

—

 

 

**

 

Net income (loss)

 

$

4,420

 

 

$

2,175

 

 

103%

 

 

$

8,213

 

 

$

(181

)

 

**

 

Net income (loss) per common share, basic

 

$

0.03

 

 

$

0.01

 

 

 

 

 

 

$

0.05

 

 

$

(0.00

)

 

 

 

 

Net income (loss) per common share, diluted

 

$

0.03

 

 

$

0.01

 

 

 

 

 

 

$

0.05

 

 

$

(0.00

)

 

 

 

 

Weighted average common shares outstanding,

Basic

 

 

169,043

 

 

 

165,703

 

 

 

 

 

 

 

168,436

 

 

 

165,566

 

 

 

 

 

Diluted

 

 

174,813

 

 

 

169,228

 

 

 

 

 

 

 

174,851

 

 

 

165,566

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANTARES PHARMA, INC.

Table 2 – CONSOLIDATED REVENUE DETAILS

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

Increase

 

 

June 30,

 

 

Increase

 

 

 

2021

 

 

2020

 

 

(Decrease)

 

 

2021

 

 

2020

 

 

(Decrease)

 

Proprietary product sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

XYOSTED®

 

$

14,739

 

 

$

10,902

 

 

35%

 

 

$

29,128

 

 

$

19,905

 

 

46%

 

OTREXUP®

 

 

3,426

 

 

 

3,944

 

 

(13)%

 

 

 

6,994

 

 

 

7,507

 

 

(7)%

 

NOCDURNA®

 

 

788

 

 

 

—

 

 

 

100%

 

 

 

1,563

 

 

 

—

 

 

 

100%

 

Total proprietary product sales

 

 

18,953

 

 

 

14,846

 

 

28%

 

 

 

37,685

 

 

 

27,412

 

 

37%

 

Partnered product sales

 

 

8,951

 

 

 

9,819

 

 

(9)%

 

 

 

19,354

 

 

 

24,350

 

 

(21)%

 

Total product sales

 

 

27,904

 

 

 

24,665

 

 

13%

 

 

 

57,039

 

 

 

51,762

 

 

10%

 

Development and licensing revenue

 

 

7,167

 

 

 

2,687

 

 

167%

 

 

 

12,151

 

 

 

4,442

 

 

174%

 

Royalties

 

 

9,907

 

 

 

5,032

 

 

97%

 

 

 

17,871

 

 

 

9,259

 

 

93%

 

Total revenue

 

$

44,978

 

 

$

32,384

 

 

39%

 

 

$

87,061

 

 

$

65,463

 

 

33%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5 of 7

 

 

 

 

ANTARES PHARMA, INC.

Table 3 – CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

 

 

 

 

June 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

45,126

 

 

$

53,137

 

Accounts receivable

 

 

54,224

 

 

 

42,221

 

Inventories

 

 

18,644

 

 

 

18,216

 

Contract assets

 

 

5,725

 

 

 

8,140

 

Prepaids and other current assets

 

 

4,244

 

 

 

4,877

 

Property and equipment, net

 

 

25,590

 

 

 

24,020

 

Deferred tax assets

 

 

45,249

 

 

 

46,982

 

Other assets

 

 

13,817

 

 

 

14,938

 

Total Assets

 

$

212,619

 

 

$

212,531

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

46,487

 

 

$

43,032

 

Long-term debt

 

 

26,151

 

 

 

40,899

 

Other liabilities

 

 

7,953

 

 

 

9,485

 

Stockholders’ equity

 

 

132,028

 

 

 

119,115

 

Total Liabilities and Stockholders’ Equity

 

$

212,619

 

 

$

212,531

 

 

 

 

 

 

 

 

 

 

 

6 of 7

 

 GRAPHIC 3 gzvmw0bm1tz5000001.jpg GRAPHIC begin 644 gzvmw0bm1tz5000001.jpg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end EX-101.SCH 4 atrs-20210805.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 atrs-20210805_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 atrs-20210805_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 atrs-8k_20210805_htm.xml IDEA: XBRL DOCUMENT 0001016169 2021-08-05 2021-08-05 false 0001016169 8-K 2021-08-05 ANTARES PHARMA, INC. DE 1-32302 41-1350192 100 Princeton South Suite 300 Ewing NJ 08628 (609) 359-3020 false false false false Common Stock, par value $0.01 per share ATRS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 05, 2021
Cover [Abstract]  
Entity Registrant Name ANTARES PHARMA, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001016169
Document Period End Date Aug. 05, 2021
Entity Emerging Growth Company false
Entity File Number 1-32302
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1350192
Entity Address, Address Line One 100 Princeton South
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Ewing
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08628
City Area Code (609)
Local Phone Number 359-3020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ATRS
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports atrs-8k_20210805.htm atrs-20210805.xsd atrs-20210805_lab.xml atrs-20210805_pre.xml atrs-ex991_19.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atrs-8k_20210805.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "atrs-8k_20210805.htm" ] }, "labelLink": { "local": [ "atrs-20210805_lab.xml" ] }, "presentationLink": { "local": [ "atrs-20210805_pre.xml" ] }, "schema": { "local": [ "atrs-20210805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atrs", "nsuri": "http://www.antarespharma.com/20210805", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20210805.htm", "contextRef": "C_0001016169_20210805_20210805", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20210805.htm", "contextRef": "C_0001016169_20210805_20210805", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.antarespharma.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-041202-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-041202-xbrl.zip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